HOUSTON, March 4, 2004 (PRIMEZONE) -- Encysive Pharmaceuticals (Nasdaq:ENCY) announced today that Stephen L. Mueller, Encysive Pharmaceuticals Vice President of Finance and Administration, will speak at the 24th Annual SG Cowen Health Care Conference on Tuesday, March 9, 2004 at 1:15 p.m. ET and again at 2:15 p.m. ET.
A webcast of the presentation will be provided by SG Cowen and may be viewed in real time at www.sgcowen.com. Alternatively, the webcast can be accessed on Encysive Pharmaceuticals' website at (www.encysive.com).
About Encysive Pharmaceuticals Inc.
Encysive is a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs, is recognized for our expertise in small molecule drug development and vascular biology. Argatroban, our first FDA-approved product, is being marketed by GlaxoSmithKline for heparin-induced thrombocytopenia. Encysive is in Phase III development of the endothelin antagonist, sitaxsentan, for pulmonary arterial hypertension. Our majority-owned affiliate, Revotar Biopharmaceuticals AG, is in Phase II development with the selectin antagonist bimosiamose in asthma, psoriasis and atopic dermatitis. Encysive has several other research and development programs ongoing for a range of cardiovascular and inflammatory diseases. To learn more about Encysive Pharmaceuticals please visit our web site: www.encysive.com.
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Among those risks, trends and uncertainties are timing and cost of our clinical trials, attainment of research and clinical goals and milestones of product candidates, attainment of required government approvals, sales levels of our products and availability of financing, and revenues sufficient to fund development of product candidates and operations. In particular, careful consideration should be given to cautionary statements made in the various reports Encysive Pharmaceuticals, including as Texas Biotechnology Corporation, has filed with the Securities and Exchange Commission. The company undertakes no duty to update or revise these forward-looking statements.
The Encysive Pharmaceuticals Inc. company logo can be found at http://media.primezone.com/prs/single/?pkgid=843